Expert Opinion on Emerging Drugs
October 2, 2023
Katarzyna Śladowska, Paweł Kawalec, Tomasz Brzostek et al.
4 citations
Clinical phase I-II trials published to date reported promising results for psilocybin in the treatment of patients with major depressive disorder and treatment-resistant depression, in a relatively short time after administration. However, before psilocybin is approved for use and administered to patients with depression, the results of large ongoing phase III clinical trials are needed to...
CPT: Pharmacometrics & Systems Pharmacology
October 2023
Marije E. Otto, Kirsten R Bergmann, Marieke L De Kam et al.
In clinical trials, Montgomery-Åsberg Depression Rating Scale (MADRS) questionnaire data are added up to total scores before analysis, assuming equal contribution of each separate question. Item Response Theory (IRT)-based analysis avoids this by using individual question responses to determine the latent variable (ψ), which represents a measure of depression severity. However, utilization of...
Brain, Behavior, and Immunity
October 1, 2023
Xinying Zhang, Teng He, Zifeng Wu et al.
CD38 is involved in immune responses, cell proliferation, and has been identified in the brain, where it is implicated in inflammation processes and psychiatric disorders. We hypothesized that dysfunctional CD38 activity in the brain may contribute to the pathogenesis of depression. To investigate the underlying mechanisms, we used a lipopolysaccharide (LPS)-induced depression model and...
CNS Drugs
October 1, 2023
Dania Akbar, Taeho Greg Rhee, Felicia Ceban et al.
A significant proportion of adults with major depressive disorder (MDD) do not respond to treatments which are currently used in clinical practice such as first-generation monoamine-based antidepressants. The objective of this systematic review was to assess the efficacy, safety, and mechanisms of action of AXS-05, a combination of the NMDA-receptor antagonist dextromethorphan with bupropion,...
Psychopharmacology
October 1, 2023
Youjia Qiu, Longyuan Li, Aojie Duan et al.
Nitrous oxide (N2O) has been initially confirmed by clinical trials to benefit to patients with major depressive disorder (MDD). However, there needs to be a meta-analysis to compare the efficacy and tolerability of N2O in MDD. PubMed, EMBASE, and Cochrane Library were searched for relevant studies up to Jan 1st, 2023. The meta-analysis mainly compared the outcome of the change in depression...
Clinical neuropsychiatry
October 1, 2023
Mario Miniati, Graziella Orrù, Mery Paroli et al.
7 citations
To investigate mindfulness traits/attitudes as protective factors against chronic pain related distress, depression and anxiety. Fifty patients (25 with chronic non-oncologic pain-NOP; 25 with chronic oncologic pain-COP) were administered with the following scales: Visual Analogue Scale (VAS), Pain Disability Index (PDI), Italian Questionnaire for Pain (QUID), Perceived Stress Scale (PSS),...
FOCUS: The Journal of Lifelong Learning in Psychiatry
October 1, 2023
Farhan Fancy, Nelson B Rodrigues, Joshua D. Di Vincenzo et al.
4 citations
Clinical trials have demonstrated rapid antidepressant effects with intravenous (IV) ketamine for major depressive disorder, with relatively less research specifically for bipolar depression. Herein, we describe the real-world effectiveness of repeated ketamine infusions for treatment-resistant bipolar depression. This study was conducted in a community clinic in Mississauga, Ontario (Canadian...
Journal of Affective Disorders
October 1, 2023
Olivier Brown
The recent publication in the Journal of Affective Disorders titled "Increased low-frequency brain responses to music after psilocybin therapy for depression" identified significant region-of-interest based effects of treatment in the task scans. In this letter to the editor, I am hoping to raise methodological concerns with regards to the ANOVA ROI analysis that were otherwise not acknowledged...
Cognitive Therapy and Research
September 30, 2023
Nicholas R. Harp, R James R Blair, Maital Neta
Purpose: Mindfulness-Based Stress Reduction (MBSR) is a well-known method for reducing stress and negative affect. Recently, a small, open-label trial showed that MBSR training was associated with a shift toward more positive responses to emotionally ambiguous signals (e.g., surprised expressions that convey either positive or negative meaning). Methods: Here, we test whether the MBSR-induced...
Frontiers in Psychiatry
September 28, 2023
Lauren Johansen, Paul Liknaitzky, Maja Nedeljkovic et al.
5 citations
As investigations into the efficacy of psychedelic-assisted psychotherapy to treat depression continue, there is a need to study the possible mechanisms of action that may contribute to the treatment's antidepressant effects. Through a two-round Delphi design, the current study investigated experts' opinions on the psychological mechanisms of action associated with the antidepressant effects of...